| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
9,211 |
7,168 |
$567K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
1,945 |
1,820 |
$183K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
2,481 |
2,468 |
$81K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
2,975 |
2,719 |
$40K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
3,541 |
1,826 |
$39K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
3,376 |
3,110 |
$38K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
395 |
395 |
$35K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
330 |
330 |
$31K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
971 |
804 |
$31K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
468 |
468 |
$30K |
| U0001 |
Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel |
3,103 |
2,859 |
$21K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
473 |
463 |
$12K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
613 |
585 |
$12K |
| 99401 |
|
526 |
501 |
$10K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,976 |
1,844 |
$9K |
| 93000 |
|
607 |
604 |
$8K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
71 |
68 |
$5K |
| 90674 |
|
182 |
182 |
$4K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
265 |
265 |
$3K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
244 |
227 |
$2K |
| 36410 |
|
194 |
181 |
$2K |
| 99443 |
|
18 |
18 |
$2K |
| 95911 |
|
22 |
12 |
$2K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
133 |
101 |
$2K |
| 95886 |
|
22 |
12 |
$1K |
| 36415 |
Collection of venous blood by venipuncture |
739 |
709 |
$1K |
| 90688 |
|
47 |
47 |
$756.38 |
| 90756 |
|
21 |
21 |
$574.90 |
| 99490 |
Ccm add 20min |
13 |
12 |
$461.68 |
| 90656 |
|
12 |
12 |
$250.47 |
| G0444 |
Annual depression screening, 5 to 15 minutes |
151 |
151 |
$181.04 |
| 99050 |
|
20 |
17 |
$117.00 |
| G9820 |
Documentation of a chlamydia screening test with proper follow-up |
28 |
28 |
$0.00 |